Ultrastructural effects of calcitonin on osteoclasts in tissue culture

Kallio, D.M.; Garant, Philias R.; Minkin, Cedric

doi:10.1016/s0022-5320(72)90017-2

Cited by 171 publications

(67 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As well, a decrease in ACP activity and development of the clear zone took place. Ultrastructural studies have shown that the ruffled border area of osteoclasts decreases (HOLTROP et al, 1974) or disappears (KALLIO et al, 1972;HOLTROP et al, 1974) in organ culture by calcitonin treatment.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of Osteoclastic Bone Resorption by Calcitonin in the Cultured Medullary Bone of Laying Hens.

1993

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Inhibition of Osteoclastic Bone Resorption by Calcitonin in the Cultured Medullary Bone of Laying Hens.

1993

View full text Add to dashboard Cite

“…It essentially reduces blood calcium and inhibits resorption activity by suppressing osteoclast formation and attachment in bone (Kallio et al, 1972;de Paula and Rosen, 2010). Since 1980's, calcitonin from salmon having similarity with human calcitonin, is used for the treatment of osteoporosis.…”

Section: Calcitoninmentioning

confidence: 99%

Marine Natural Products: New Avenue in Treatment of Osteoporosis

Chaugule¹,

Indap²,

Chiplunkar

2017

Front. Mar. Sci.

View full text Add to dashboard Cite

Bone metabolism is a physiological process that maintains the skeletal integrity and bone functions. Skeletal integrity is always balanced by two key cell types-bone resorbing osteoclasts and bone-forming osteoblasts. Imbalance between generation and function of osteoclasts and osteoblasts often leads to pathological conditions such as osteoporosis, osteopetrosis, Paget's disease. Osteoporosis is one of the most common age-related diseases characterized by decreased bone mineral density and microarchitectural deterioration. Current therapies are indeed effective in preventing bone loss but are also followed by side effects. Since many years, marine organisms have been considered as a good source of bioactive molecules or compounds with potential pharmaceutical properties. Marine Natural Products (MNPs) derived from various marine resources such as marine cyanobacteria, dinoflagellates, algae, sponges, soft corals, molluscs, fishes, and mangroves had shown profound effect on bone metabolism through inhibiting osteoclastogenesis and up-regulating osteoblastogenesis via modulating RANK/RANKL/OPG pathway. Amongst the pre-clinically investigated MNPs for management of osteoporosis, very few are under phase I clinical trials. This review discusses the currently available pharmacological drugs and there major health concern in osteoporosis treatment. It further gives an insight into various marine resources and marine-derived bioactive products, depicting their mechanism of action, functional role, and how these can be exploited for the treatment of osteoporosis.

show abstract

“…This indicates that apoptosis is not the sole method by which osteoclastic resorption is stopped (Kallio et al, 1972). However, it can be induced by nitric oxide, through protein kinase A and eventual caspase-3 activation (Kanaoka et al, 2000).…”

Section: Apoptosis: Regulation Of Remodelingmentioning

confidence: 99%